The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

Our team will be presenting three abstracts at the conference, showcasing our latest research findings.

Read our news release: Imagia Canexia Health Announces Three Abstracts to be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Latest Research Findings

“Our ability to accelerate access to precision care by combining AI expertise with advanced molecular biopsy solutions provides our hospital and lab partners with actionable insights to deliver cost-effective cancer testing to patients no matter where they seek treatment. The abstracts accepted for presentation at AACR 2023 will highlight new learnings and tools that demonstrate our ongoing commitment to close the health equity gap in cancer.” Vincent Funari, Chief Scientific Officer

Date: April 14-19, 2023
Location: Orange County Convention Center in Orlando, Florida
Booth: 366

Abstract Presentations:

Title: Development of a one-step molecular classifier for endometrial carcinoma using an amplicon-based gene panel and next generation sequencing technology

Presenter: Dr. Melissa McConechy

The original ProMisE (pragmatic molecular classification tool) test requires multiple steps to derive the molecular subtypes for endometrial cancer. Clinically, tests can be performed at multiple centres and at different times, and results may not provided to patients until after treatment has already begun. This defeats the purpose of molecular testing for endometrial cancer, since results can help determine more effective treatment decisions. This abstract will present a study conducted by the ICH team using a one step DNA-based test. Results were compared alongside ProMisE test results to determine if a one step test could replace current methods, while maintaining prognostic value.

Date and Time: Tuesday Apr 18, 2023 | 9:00 AM – 12:30 PM
Session Category: Clinical Research Excluding Trials Session
Session Title: Spatial Profiling, Tumor Classification, and Response Assessment
Location: Section 44
Poster Board Number: 21
Abstract Presentation Number: 4542


Title: Method for identifying microsatellite instability high DNA abnormality samples

Presenter: Dr. Rosalia Aguirre-Hernández

Tissue samples with high microsatellite instability (MSI-H) can be indicators of cancerous tumors, which are sensitive to certain types of cancer treatments. This abstract will present a method developed by the team at ICH to classify a tissue sample as being microsatellite instability high (MSI-H) without having to use normal tissue from the same person, decreasing the cost of sequencing.

Date and Time: Tuesday Apr 18, 2023 9:00 AM – 12:30 PM
Session Category: Bioinformatics / Computational Biology / Systems Biology / Convergent Science
Session Title: Algorithms and Statistical Methods
Location: Section 32
Poster Board Number: 10
Abstract Presentation Number: 4279


Title: Liquid biopsy testing in metastatic or advanced breast cancer patients during the COVID-19 pandemic

Presenter: Dr. Benjamin Furman

For Project ACTT, a population of Canadian women with metastatic breast cancer were tested using a liquid biopsy gene panel during the COVID-19 pandemic to identify biomarkers that could match them with targeted therapies. Certain mutations have been known to respond better to some targeted therapies. Results of this study will be presented outlining how earlier use of targeted therapies improve outcomes through the use of liquid biopsy. 

Date and Time: Tuesday Apr 18, 2023 | 1:30 PM – 5:00 PM
Session Category: Clinical Research Excluding Trials
Session Title: Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4
Location: Section 41
Poster Board Number: 14
Abstract Presentation Number: 5590